LYF.F EKF DIAGNOST.HLDGS.LS-01
- Market cap
- EUR 117M
- P/E
- 27.4x
- P/B
- 1.39x
- ROE
- 3.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is LYF.F undervalued?
Graham numberLYF.F trades 30.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EKF DIAGNOST.HLDGS.LS-01 fundamental analysis
No fundamental analysis for EKF DIAGNOST.HLDGS.LS-01 yet.
EKF DIAGNOST.HLDGS.LS-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EKF DIAGNOST.HLDGS.LS-01
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such…
Full company profileEKF DIAGNOST.HLDGS.LS-01 financial statements
EKF DIAGNOST.HLDGS.LS-01 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 81.8M | 66.6M | 52.6M | 50.2M | 51.6M |
| Gross Profit | 39.4M | 24.0M | 23.9M | 24.1M | 26.5M |
| Operating Income | 21.8M | 1.78M | 4.34M | 6.28M | 6.98M |
| EBITDA | - | -2.18M | 7.68M | 11.2M | 12.6M |
| Net Income | 15.9M | -10.1M | 2.35M | 6.24M | 2.12M |
| EPS | 0.03 | -0.02 | 0.01 | 0.01 | 0.00 |
| Balance Sheet | |||||
| Total Assets | 115M | 89.3M | 80.8M | 81.7M | 81.1M |
| Total Liabilities | 20.4M | 14.8M | 12.6M | 8.53M | 10.9M |
| Shareholders' Equity | 94.1M | 73.3M | 67.1M | 72.3M | 69.1M |
| Cash & Short-term Investments | 20.3M | 9.21M | 6.02M | 13.0M | 13.7M |
| Cash Flow | |||||
| Operating Cash Flow | 10.2M | 9.69M | 6.31M | 13.7M | 9.71M |
| Capital Expenditure | 5.65M | 5.83M | 6.98M | 2.76M | 2.37M |
| Free Cash Flow | 4.59M | 3.86M | -664K | 10.9M | 7.34M |
| Ratios | |||||
| ROE | 16.8% | -13.8% | 3.5% | 8.6% | 3.1% |
| ROA | 13.8% | -11.3% | 2.9% | 7.6% | 2.6% |
| Net Profit Margin | 19.4% | -15.2% | 4.5% | 12.4% | 4.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
EKF DIAGNOST.HLDGS.LS-01 dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Nov 2, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | GBP 5.45M | 0.01 | 231.5% |
| 2022 | GBP 5.46M | 0.01 | - |
| 2021 | GBP 5.10M | 0.01 | 32.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns EKF DIAGNOST.HLDGS.LS-01
- Insiders 3.94%
- Institutions 72.76%
- Public & others 23.29%
- Shares outstanding 428M
- Free float 352M
EKF DIAGNOST.HLDGS.LS-01 company profile
- Company name
- EKF DIAGNOST.HLDGS.LS-01
- Ticker
- LYF.F
- ISIN
- GB0031509804
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 308
- Fiscal year end
- December
- Address
- Avon House, Cardiff, United Kingdom, CF64 2EZ
- Phone
- 44 29 2071 0570
- Website
- ekfdiagnostics.com
About EKF DIAGNOST.HLDGS.LS-01
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test HbA1c, fully automated hemoglobin A1c analyzer for the monitoring and management of diabetes; and STAT-Site W Beta-Hydroxybutyrate analyzer. In addition, the company offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; Lactate Scout Vet, a handheld lactate analyzer for veterinary care; Hemo Vet, a point-of-care hemoglobin and hematocrit analyzer; Lactate Scout Sport, a lactate analyzer for sports performance; Biosen series for sports; and EKF Link, a data management solution that integrates point-of-care analyzers. Further, it offers Beta-Hydroxybutyrate LiquiColor for monitoring ketosis; RaPET, a range of immunoassay kits; QuStick Strep A for Strep A infection treatment; Hema-Screen Lab Pack for detection of colorectal cancer; PrimeStore MTM, a molecular transport medium that preserves and stabilizes DNA and RNA; Uri-Trak 120M urine analyzer; and clinical chemistry reagents, controls, and standards. Additionally, the company provides precision fermentation, custom bioprocessing, and contract manufacturing solutions; and diagnostic enzymes that include arylacylamidase, beta-hydroxybutyrate dehydrogenase, and salicylate hydroxylase. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
EKF DIAGNOST.HLDGS.LS-01 management
3- Mr. Julian Huw Baines M.B.E.Executive Chairman · born 1964
- Mr. Gavin Joseph JonesCEO & Director · born 1980
- Ms. Helen Mary Kinsey Jones F.C.A.CFO & Director · born 1979